Oncor study of bladder cancer microsatellite DNA test to begin in several months.
This article was originally published in The Gray Sheet
Executive Summary
ONCOR PMA FOR BLADDER CANCER MICROSATELLITE DNA TEST may be submitted as early as 1997 but more likely will not be ready until 1998 due to the pursuit of a patient screening indication for the test, the Gaithersburg, Maryland company says. Oncor is hoping to pursue approval of the test for screening in high-risk populations, which would require more extensive follow-up data than a patient monitoring claim, the company says. However, the test is still in early stages of development, Oncor notes, and the final form of the premarket approval application has yet to be determined.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.